Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc. (REGN)Business Wire • 05/16/24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/16/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Regeneron Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/15/24
Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)Seeking Alpha • 05/14/24
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)GlobeNewsWire • 05/13/24
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 WeeksGlobeNewsWire • 05/08/24
Down -8.24% in 4 Weeks, Here's Why Regeneron (REGN) Looks Ripe for a TurnaroundZacks Investment Research • 04/29/24
Countdown to Regeneron (REGN) Q1 Earnings: A Look at Estimates Beyond Revenue and EPSZacks Investment Research • 04/29/24
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal DiseasesGlobeNewsWire • 04/29/24